Results 41 to 50 of about 4,836 (184)

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

JEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz, Simonetta I. Gaumond, Joaquin J. Jimenez   +2 more
wiley   +1 more source

Management of Plaque Psoriasis: A Review and Comparison of IL-23 Inhibitors

European Medical Journal Dermatology, 2020
With the recent advancements of biologic therapies that block IL-23, there is increasing need for analysis of which biologics are most efficacious in treatment of plaque psoriasis.
Nicole L. Bolick, Rima I. Ghamrawi, Steven R. Feldman   +2 more
doaj  

Efficacy and safety of risankizumab for active psoriatic arthritis : 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

, 2022
Objectives Risankizumab is an interleukin-23 inhibitor under study for the treatment of patients with psoriatic arthritis (PsA). The phase 3 KEEPsAKE 2 trial investigated the efficacy and safety of risankizumab versus placebo in patients with active PsA ...
Papp, Kim, Wang, Zailong, Ostor, Andrew, Alperovich, Gabriela, Soliman, Ahmed M., Blanco, Ricardo, Asnal, Cecilia, Van den Bosch, Filip, Lu, Wenjing, Eldred, Ann, Barcomb, Lisa, Aelion, Jacob, Kivitz, Alan   +12 more
core   +1 more source

Impact of BMI and Body Weight on Clinical Outcomes in Psoriasis: A Post Hoc Analysis of the RESOLVE Observational Study

JEADV Clinical Practice, EarlyView.
This post‐hoc analysis of the Greek real‐world ReSOLVE study compared clinical and patient‐reported outcomes by body weight (< 100 kg vs. ≥ 100 kg) and BMI over 52 weeks. Patients ≥ 100 kg showed delayed PASI and sPGA responses at W24 and W52, while BMI had little impact. Quality‐of‐life improvements were substantial, though early gains were smaller in
Pantelis Panagakis, Kanella Kalapothakou, Despina Exadactylou, Ioanna Lefaki, Marina Papoutsaki, Natalia Rompoti, Dimitrios Xekardakis, Nikolaos Fekkas, Efthymios Stathatos, Athanasios Chaniotis, Electra Nicolaidou, Alexandros Stratigos, Vasiliki Chasapi   +12 more
wiley   +1 more source

Real World Use of the IL‐36 Receptor Antagonist Spesolimab: A Systematic Review and Analysis

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Spesolimab, an interleukin‐36 receptor antagonist, is approved for the treatment and prevention of generalised pustular psoriasis (GPP) flares. Its use has increasingly been reported in real‐world settings for both GPP and other inflammatory dermatoses.
Sophia A. Mense, Nicole Bavaro, Aashna Farishta, Jiaqi Chen, Raj Chovatiya   +4 more
wiley   +1 more source

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada, Yoshiko Maeda, Miyuki Hasegawa, Motonobu Sakaguchi, Takamasa Hashimoto, Teruko Narusawa, Nobuyoshi Takabayashi, Tomoko Takahashi, Taisuke Kondo, Shingo Kuroda   +9 more
wiley   +1 more source

Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study

, 2021
IL‐23‐inhibitors, such as guselkumab and risankizumab, represent the newest class of biologics approved for psoriasis. Phase III trials have shown their efficacy and safety. However, real life data are still scant. to indirectly compare the effectiveness,
Megna, Matteo, Fabbrocini, Gabriella, Ruggiero, Angelo, Cinelli, Eleonora, Matteo Megna, Gabriella Fabbrocini, Angelo Ruggiero, Eleonora Cinelli   +7 more
core   +1 more source

Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study [PDF]

, 2023
INTRODUCTION: Atopic dermatitis (AD) is a heterogeneous disease, with involvement of the T-helper cell (Th) 2, Th22, and potentially Th17 pathways, supporting the use of interleukin (IL)-23 and IL-22 blockade in AD.
Tada, Yayoi, Liu, Jie, Messina, Izabella, Tyring, Stephen K, Beeck, Stefan, Rich, Phoebe, Huang, Xiaohong, Shumack, Stephen, Jie Liu, Izabella Messina, Xiaohong Huang, Yayoi Tada, Stefan Beeck, Stephen Shumack, Phoebe Rich, Stephen K. Tyring   +15 more
core   +1 more source

Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis. [PDF]

Int J Dermatol
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Falco GM, Ippoliti E, Gori N, Caldarola G, De Simone C, Di Giorgi N, Longo PG, Galluzzo M, Bianchi L, Marcelli L, Talamonti M, Cannizzaro MV, Di Nardo L, Peris K.   +13 more
europepmc   +2 more sources

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source